Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients.
Renard
T H
TH
Department of Surgery, University of Texas, Southwestern Medical Center, Dallas.
Andrews
W S
WS
Foster
M E
ME
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000032:analysis*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D017252:CD3 Complex; D002648:Child; D002675:Child, Preschool; D006084:Graft Rejection; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007223:Infant; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology*; D008232:Lymphoproliferative Disorders / Q000209:etiology* / Q000628:therapy; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D013577:Syndrome; D014412:Tumor Virus Infections / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell